RxDoctor Payments Data

Felicia Carr, MD

Family Medicine · Savannah, GANPI 1205858750

Payments from drug & device makers

$14,658in general payments, 2019–2025

Across 932 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Amgen$1K
  • AstraZeneca$979
  • plus $7K from 50 others

What the payments were for

  • Food & beverage$14,44499%
  • Education$2141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,658 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$45,276
Medicare patients
165
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$175,332
TrulicityDulaglutide85$105,652
TradjentaLinagliptin85$87,301
EliquisApixaban42$55,571
MounjaroTirzepatide48$54,097
BiktarvyBictegrav/Emtricit/Tenofov Ala13$53,440
RybelsusSemaglutide45$43,610
JardianceEmpagliflozin35$42,530
LinzessLinaclotide39$39,561
JanuviaSitagliptin Phosphate33$25,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$23,133
RexultiBrexpiprazole17$22,325
Tresiba Flextouch U-100Insulin Degludec31$21,216
Repatha SureclickEvolocumab28$18,013
Tresiba Flextouch U-200Insulin Degludec15$16,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,718$218,942171 claims
Lilly USA, LLCTrulicity, Mounjaro$1,277$159,749133 claims
Boehringer IngelheimTradjenta, Jardiance$613$129,831120 claims
PfizerEliquis$1,122$55,57142 claims
GileadBiktarvy$11$53,44013 claims
AbbVieLinzess$1,407$39,56139 claims
MerckJanuvia, Belsomra$130$31,94348 claims
GSKTrelegy Ellipta, Breo Ellipta$590$29,72647 claims
Otsuka America Pharmaceutical, Inc.Rexulti$401$22,32517 claims
AstraZenecaFarxiga$979$13,86113 claims
Astellas Pharma US IncMyrbetriq$581$12,72119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →